



(51) International Patent Classification:
A61P 35/00 (2006.01) *C07K 16/30* (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/EP2022/053651

(22) International Filing Date:
15 February 2022 (15.02.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/149,921 16 February 2021 (16.02.2021) US

(71) Applicant: JANSSEN PHARMACEUTICA NV
[BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).


(72) Inventors: **ATTAR, Ricardo Marcos**; 1400 McKean Road, Spring House, PA 19477 (US). **BRODEUR, Scott Ronald**; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). **GANESAN, Rajkumar**; Thousand Oaks, Ventura County, California (US). **LUISTRO, Leopoldo**; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). **PHILIPPART, Ulrike**; Turnhoutseweg 30, B-2340 Beerse (BE). **PILLARISETTI, Kodandaram**; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). **JINGH, Sanjaya**; 1910 Cori Lane, Blue Bell, PA 19422 (US). **YANG, Danlin Dan Qing**; 1400 McKean Road, Spring House, Pennsylvania 19477 (US).

(74) Agent: **DUFFIELD, Stephen** et al.; Carpmaels & Ransford LLP, One Southampton Row, London WC1B 5HA (GB).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

(54) Title: TRISPECIFIC ANTIBODY TARGETING BCMA, GPRC5D, AND CD3

FIG. 29



(57) Abstract: Provided herein are multispecific antibodies that bind to BCMA, GPRC5D and CD3 and multispecific antigen-binding fragments thereof. Also described are related polynucleotides capable of encoding the provided multispecific antibodies or multispecific antigen-binding fragments, cells expressing the provided multi specific antibodies or multispecific antigen-binding fragments, as well as associated vectors and detectably labeled multispecific antibodies or multispecific antigen-binding fragments. In addition, methods of producing and using the provided multispecific antibodies and multispecific antigen-binding fragments are described. Further provided herein are antibodies that bind to BCMA and antigen-binding fragments thereof. Also described are related polynucleotides capable of encoding the provided BCMA-specific antibodies or antigen-binding fragments, cells expressing the provided BCMA-specific antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled BCMA-specific antibodies or antigen-binding

[Continued on next page]

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

29 September 2022 (29.09.2022)

fragments. In addition, methods of producing and using the provided BCMA-specific antibodies and antigen-binding fragments are described.